... Here, we describe the sustained response to second-line crizotinib in two patients with echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged advanced NSCLC after failure of the first-line alectinib therapy with no secondary ALK mutations... We speculate that the sustained response to crizotinib in our cases was primarily owing to the absence of ALK resistance mutations. However, we cannot completely rule out the activation of other alternative pathways, as tumor rebiopsies were not performed after developing resistance to alectinib. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2020.01.003
Authors: Jing Zheng, Wenjia Sun, Wenhong Chen, Jianying Zhou, Jianya Zhou
